The cellular level of p-Smad3 as an indicator of the canonical TGFβ-smad2/3 pathways, and p-Akt, active RhoA, p-ERK, p-JNK as indicators of non-canonical TGFβ pathways in GBM cells treated with exogenous TGFβ were evaluated. The gene discussed is SMAD3; the disease is glioblastoma.